Ocumension Therapeutics (SEHK:1477) - Aandelenkoers, Nieuws & Analyse

1477 Overzicht aandelen

Ocumension Therapeutics is, samen met haar dochterondernemingen, actief als een oftalmologisch farmaceutisch platformbedrijf in de Volksrepubliek China.

Over het bedrijf

1477 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Trading at 58.9% below our estimate of its fair value

Earnings are forecast to grow 101.88% per year

Earnings have grown 50.6% per year over the past 5 years

Analysts in good agreement that stock price will rise by 84.5%

Risicoanalyse

Shareholders have been diluted in the past year

Ocumension Therapeutics Concurrenten

YiChang HEC ChangJiang Pharmaceutical

SEHK:1558

HK$8.0b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.9b

Tong Ren Tang Technologies

SEHK:1666

HK$6.6b

Consun Pharmaceutical Group

SEHK:1681

HK$7.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ocumension Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	HK$5.38
52 Week Hoogtepunt	HK$7.94
52 Week Laag	HK$4.13
Bèta	0.77
11 maand verandering	-21.11%
3 maanden verandering	-25.38%
1 Jaar Verandering	-30.58%
33 jaar verandering	-63.99%
5 jaar verandering	n/a
Verandering sinds IPO	-85.46%

Recent nieuws en updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

Rendement voor aandeelhouders

	1477	HK Pharmaceuticals	HK Markt
7D	-7.2%	-7.2%	-1.0%
1Y	-30.6%	-2.9%	15.0%

Rendement versus industrie: 1477 underperformed the Hong Kong Pharmaceuticals industry which returned -2.9% over the past year.

Rendement versus markt: 1477 underperformed the Hong Kong Market which returned 15% over the past year.

Prijsvolatiliteit

Is 1477's price volatile compared to industry and market?
1477 volatility
1477 Average Weekly Movement	9.9%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 1477 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatiliteit in de loop van de tijd: 1477's weekly volatility (10%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	477	Victor Liu	www.ocumension.com

Ocumension Therapeutics is, samen met haar dochterondernemingen, actief als een oftalmologisch farmaceutisch platformbedrijf in de Volksrepubliek China. Het ontdekt, ontwikkelt en commercialiseert therapieën voor oogheelkundige patiënten. Het portfolio omvat producten en geneesmiddelen voor de behandeling van chronische niet-infectieuze uveïtis, blefaritis, infectieuze en allergische conjunctivitis, diabetisch maculair oedeem, droge ogen, glaucoom en oculaire hypertensie, postoperatieve ontsteking, choroïdale neovascularisatie, bacteriële conjunctivitis, retinitis pigmentosa, acuut glaucoom, leeftijdsgebonden maculadegeneratie, cornea afstoting, bijziendheid en optische neuritis.

Ocumension Therapeutics Samenvatting

Hoe verhouden de winst en inkomsten van Ocumension Therapeutics zich tot de beurswaarde?
1477 fundamentele statistieken
Marktkapitalisatie	HK$4.41b
Inkomsten(TTM)	-HK$353.70m
Inkomsten(TTM)	HK$340.08m

13.0x

P/S-verhouding

-12.5x

Koers/Winstverhouding

Is 1477 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1477 resultatenrekening (TTM)
Inkomsten	CN¥310.29m
Kosten van inkomsten	CN¥129.44m
Brutowinst	CN¥180.86m
Overige uitgaven	CN¥503.58m
Inkomsten	-CN¥322.73m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.39
Brutomarge	58.29%
Nettowinstmarge	-104.01%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 1477 op de lange termijn?

Bekijk historische prestaties en vergelijking

1477 Overzicht aandelen

Beloningen

Risicoanalyse

Ocumension Therapeutics Concurrenten

SEHK:1558

HK$8.0b

SEHK:2877

HK$6.9b

SEHK:1666

HK$6.6b

SEHK:1681

HK$7.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024